Format

Send to

Choose Destination
F1000Res. 2018 Feb 1;7:132. doi: 10.12688/f1000research.12120.1. eCollection 2018.

NAD + biosynthesis, aging, and disease.

Author information

1
Department of Developmental Biology, Washington University School of Medicine, St. Louis, USA.

Abstract

Nicotinamide adenine dinucleotide (NAD +) biosynthesis and its regulation have recently been attracting markedly increasing interest. Aging is marked by a systemic decrease in NAD + across multiple tissues. The dysfunction of NAD + biosynthesis plays a critical role in the pathophysiologies of multiple diseases, including age-associated metabolic disorders, neurodegenerative diseases, and mental disorders. As downstream effectors, NAD +-dependent enzymes, such as sirtuins, are involved in the progression of such disorders. These recent studies implicate NAD + biosynthesis as a potential target for preventing and treating age-associated diseases. Indeed, new studies have demonstrated the therapeutic potential of supplementing NAD + intermediates, such as nicotinamide mononucleotide and nicotinamide riboside, providing a proof of concept for the development of an effective anti-aging intervention.

KEYWORDS:

Biosynthesis Aging; NAD+

Conflict of interest statement

No competing interests were disclosed.No competing interests were disclosed.No competing interests were disclosed.

Publication type

Publication type

Supplemental Content

Full text links

Icon for F1000 Research Ltd Icon for PubMed Central
Loading ...
Support Center